Benjamin L. Oakes

❤️‍🩹 New guideline from @ACCinTouch, @American_Heart, and other leading medical organizations reflects a key shift in cardiovascular care: → Earlier LDL-C testing → Targeting lower LDL-C levels based on risk → Greater focus on prevention over time More in our thread 👇

Hypercholesterolemia is a major driver of cardiovascular disease. This @BioWorld article covers our work to advance STX-1150 – designed to durably lower LDL-C via epigenetic silencing of PCSK9 – into the clinic and meaningfully change how #CVD is treated. bioworld.com/articles/72818…

At Scribe, we believe the standard of cardiovascular care today needs a paradigm shift. @CardioBusiness spotlights our development of novel #CRISPR-based medicines that target the key lipid drivers of ASCVD – check out the article preview and link below. 👇

Read the latest in @LongevityTech about our second success milestone with @EliLillyandCo and the demonstration of “steady, disciplined progress toward a future where genetic medicine plays a central role in how we manage aging and chronic disease." longevity.technology/news/gene-edit…

Dr. Jennifer Doudna, Nobel laureate & Scribe co-founder, is one of America’s greatest innovators. Our CEO and co-founder @BenjaminLOakes spoke with @Forbes about her unmatched impact on science and medicine. Check out Dr. Doudna’s Forbes 250 profile in the links below 👇

We achieved a second success milestone with @EliLillyandCo in our collaboration to advance in vivo #CRISPR-based therapies for neurological and neuromuscular disorders. Progress like this matters because patients cannot wait. More details in thread 🧵 #CRISPR #GeneEditing

Our thanks to @BiopharmaTrend for highlighting our newest preprint! We detail the engineering behind our ELXR epigenetic silencing tech – including a new control layer for the CasX-based epigenetic silencer. The result: Improved precision for CRISPR-based therapeutics. Details⬇️

Can #CRISPR genetic medicine solve cardiovascular disease? We’re advancing STX-1150 into first-in-human clinical trials to target LDL-C, one of the biggest drivers of heart disease, and reduce ASCVD risk without permanently changing the DNA. @LongevityTech article below 👇

Read more about our approach to improving cardiovascular health and longevity in this @LongevityTech piece by @mrdannysullivan: longevity.technology/news/epigeneti… #HeartDisease #OurHearts #HeartMonth

As #AmericanHeartMonth approaches, we're preparing to advance a new therapy for cardiovascular disease. STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics. More in @endpts👇

Scribe’s CRISPR-based cholesterol reduction therapy is part of a three-pronged approach to combating cardiovascular disease. longevity.technology/news/epigeneti… #longevity #CRISPR #cholesterol #CVD #heartdisease

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

Happening TODAY at #JPM2026! Don’t miss our CEO @BenjaminLOakes’ presentation at the @jpmorgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT). #JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD @FierceBiotech @LifeSciEvents

Kick off JPM Week with us this Sunday! Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @EliLillyandCo, Alphabet Health, ProBio, and more. Details below 🧬👇

Coming up next week at #JPM2026: Our CEO @BenjaminLOakes will speak at the @jpmorgan Healthcare Conference & @FierceBiotech @LifeSciEvents JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT! Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Could a single treatment lower heart disease risk by up to 90%? At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @BenjaminLOakes recently shared our progress at the @TCTConference.

Our co-founder & CEO @BenjaminLOakes will present at the 44th Annual @jpmorgan Healthcare Conference. Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026. #JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Thanks to @DrugDiscovNews for the great coverage featuring Scribe CEO @BenjaminLOakes' thoughts on the current state and future potential of AI-assisted CRISPR technologies. Read the full piece here: drugdiscoverynews.com/can-ai-take-th…

As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful. Happy Thanksgiving! 🦃

Thanks to @mrdannysullivan for the conversation highlighting the critical question: can genetic medicine help us better treat and prevent ASCVD? Lipid levels are genetically driven for many people, and while today’s treatments work, they rely on lifelong, burdensome adherence. I believe, next-gen CRISPR and epigenetic technologies may finally offer durable protection that gives patients real agency and ownership over their health. Appreciate the chance to talk about how we’re working to make that future real @scribetx .